Gerard Bruin
Overview
Explore the profile of Gerard Bruin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1251
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gresham J, Bruin G, Picci M, Bechtold-Peters K, Dimke T, Davies E, et al.
J Pharm Sci
. 2024 Sep;
113(12):3447-3456.
PMID: 39306036
The effects of subcutaneous (SC) injection parameters such as drug formulation volume, viscosity and injection rate on therapeutic performance and tolerability have not been established for any drug product. In...
2.
Ball K, Bruin G, Escandon E, Funk C, Pereira J, Yang T, et al.
Drug Metab Dispos
. 2022 Feb;
50(6):858-866.
PMID: 35149542
Characterization of the pharmacokinetics and biodistribution of therapeutic proteins (TPs) is a hot topic within the pharmaceutical industry, particularly with an ever-increasing catalog of novel modality TPs. Here, we review...
3.
Bolleddula J, Brady K, Bruin G, Lee A, Martin J, Walles M, et al.
Drug Metab Dispos
. 2022 Feb;
50(6):837-845.
PMID: 35149541
Therapeutic proteins (TPs) comprise a variety of modalities, including antibody-based drugs, coagulation factors, recombinant cytokines, enzymes, growth factors, and hormones. TPs usually cannot traverse cellular barriers and exert their pharmacological...
4.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, et al.
Br J Dermatol
. 2022 Jan;
186(6):942-954.
PMID: 34981829
Background: Obesity is a common comorbidity of psoriasis and can attenuate response to biologic treatment. Objectives: To investigate the efficacy, safety and tolerability of secukinumab 300 mg every 2 weeks...
5.
Sigurgeirsson B, Browning J, Tyring S, Szepietowski J, Rivera-Diaz R, Effendy I, et al.
Dermatol Ther
. 2021 Dec;
35(3):e15285.
PMID: 34954841
Convenient administration is an important factor for treatment adherence in patients with psoriasis. MATURE study reports the efficacy, safety, tolerability, and pharmacokinetics (PKs) of secukinumab 300 mg 2 ml autoinjector...
6.
Kolbinger F, Di Padova F, Deodhar A, Hawkes J, Huppertz C, Kuiper T, et al.
Pharmacol Ther
. 2021 Jun;
229:107925.
PMID: 34171337
Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases, each commonly manifesting as a spectrum of symptoms, complications, and comorbidities that arise differently in individual patients. Drugs targeting inflammatory...
7.
Sigurgeirsson B, Schakel K, Hong C, Effendy I, Placek W, Rich P, et al.
J Dermatolog Treat
. 2021 Apr;
33(3):1718-1726.
PMID: 33896356
Background: Evidence shows good tolerability in patients for subcutaneous injection volumes up to 3 mL. Objectives: We investigated efficacy, pharmacokinetics, and tolerability of secukinumab 300 mg/2 mL pre-filled syringe (PFS)...
8.
9.
10.
Bruin G, Hockey H, La Stella P, Sigurgeirsson B, Fu R, Patekar M, et al.
Br J Clin Pharmacol
. 2019 Oct;
86(2):338-351.
PMID: 31658377
Aims: The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of secukinumab with different devices for subcutaneous (s.c.) administration of 2 mL. Methods: A phase...